Project: A tailored and rational approach for treating cancer patients with a YAP-TEAD inhibitor

To deliver a first-in-class drug for the therapy of malignant mesothelioma, non-small cell lung cancer (NSCLC), triple-negative breast cancer and pediatric cancer, we will: Deliver a clinical development drug candidate blocking YAP-TEAD interaction Develop a companion biomarker for patient selection and drug efficacy based on - a genomic signature - YAP nuclear localization by immunohistochemistry Show preclinical efficacy as single agent or in combination with standard of care

Acronym	TheraYAP (Reference Number: 10483)
Duration	01/10/2016 - 01/07/2019
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 5

Project partner

Number	Name	Role	Country
24225	INVENTIVA	Coordinator	France
24226	ATRYS HEALTH SA	Partner	Spain
24227	XENTECH	Partner	France